AI Article Synopsis
- Nail psoriasis (NP) is a significant issue for patients with psoriasis, and complete resolution is a key treatment goal assessed at weeks 24-26.
- A network meta-analysis compared six biologics to determine their efficacy in achieving complete resolution of NP in patients with moderate-to-severe psoriasis.
- Results showed that ixekizumab had the highest probability (46.5%) of complete resolution, followed by brodalumab and adalimumab, while infliximab had the lowest probability (0.8%).
Article Abstract
Background: Nail psoriasis (NP) is common and of high importance in patients with psoriasis. Complete resolution of NP at week 24‒26 is an unambiguous nail outcome accessible for indirect treatment comparison of biologics.
Objective: To evaluate the comparative efficacy of approved biologics in achieving complete resolution of NP at week 24‒26.
Methods: A network meta-analysis (NMA) was conducted to indirectly compare the efficacy of six biologics in achieving complete resolution of NP at week 24‒26 in patients with moderate-to-severe psoriasis and concomitant NP. Complete resolution of NP was defined as a score of zero on the Nail Psoriasis Severity Index (NAPSI), modified NAPSI (mNAPSI) or Physician's Global Assessment of Fingernails (PGA-F).
Results: The probability of achieving complete resolution of NP was highest for ixekizumab (46.5%; 95% credibility interval [CrI] 35.1‒58.0; Surface Under the Cumulative RAnking curve [SUCRA] 97%), followed by brodalumab (37.0%; 17.0‒61.0; 79%), adalimumab (28.3%; 24.4‒32.4; 62%), guselkumab (27.7%; 21.1‒35.1; 58%), ustekinumab (20.8%; 10.2‒35.2; 37%), and infliximab (0.8%; 0.0‒8.9; 17%).
Conclusion: In patients with moderate-to-severe psoriasis and concomitant NP, ixekizumab has the greatest likelihood among approved biologics of achieving complete resolution of NP at week 24‒26. Findings should be interpreted carefully because of inherent study limitations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09546634.2021.1892024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ectopic thyroid tissue in the airway: a case report.
BMC Pulm Med
January 2025
Department of Respiratory Medicine, The Second Hospital of Jilin University, No. 4026 Yatai street, Changchun, 130041, Jilin, China.
Background: Ectopic thyroid tissue (ETT) is a rare congenital anomaly caused by the abnormal embryonic migration of thyroid tissue, leading to its presence outside its usual pretracheal location. This condition can lead to diagnostic challenges, especially when located within the airway, as it mimics other respiratory disorders such as asthma.
Case Presentation: We report the case of a 69-year-old man with endotracheal ETT presenting with severe dyspnea, and the lesion was initially suspected to be malignant.
Superior Outcomes with Ultrasound-Guided Hyaluronidase for Impending Filler-Induced Facial Skin Necrosis: A Systematic Review and Pilot Meta-Analysis.
Aesthetic Plast Surg
January 2025
Department of Plastic and Reconstructive Surgery, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Background: Hyaluronidase remains the mainstay treatment for impending filler-induced facial skin necrosis. Complete resolution of impending skin necrosis following hyaluronidase injection is estimated to be around 77.8%.
View Article and Find Full Text PDFPosterior fossa ring-enhancing lesions in the adult immunocompetent host: illustrative cases, systematic review, and proposed diagnostic algorithm.
AJNR Am J Neuroradiol
January 2025
Department of Neurology, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.
Purpose: Posterior fossa ring-enhancing lesions (PFREL) in the adult immunocompetent hosts pose a diagnostic challenge. We aimed to evaluate the spectrum of PFREL etiologies and propose a diagnostic algorithm.
Methods: This study involved a retrospective analysis of PFREL cases from our institution (January 2023 to April 2024) and a systematic literature review conducted using Embase and PubMed databases following the PRISMA 2020 guidelines.
Carrier-free nanoparticles for cancer theranostics with dual-mode magnetic resonance imaging/fluorescence imaging and combination photothermal and chemodynamic therapy.
Int J Pharm
January 2025
The Comprehensive Breast Care Center, The Second Affiliated Hospital of Xi'an Jiaotong University, No.157 Xiwu Road, Xi'an, Shaanxi 710004, China. Electronic address:
Both photothermal therapy (PTT) and chemodynamic therapy (CDT) are designed to focus their antitumor effect on only the tumor site, thereby minimizing unwanted severe damage to healthy tissue outside the tumor. However, each monotherapy is limited in achieving complete tumor eradication, resulting in tumor recurrence. The combination of multiple therapies may help to overcome the limitations of single therapy, improve the chances of complete tumor eradication, and reduce the risk of recurrence.
View Article and Find Full Text PDFPattern Separation and Pattern Completion Within the Hippocampal Circuit During Naturalistic Stimuli.
Hum Brain Mapp
February 2025
Research Center for Social Computing and Information Retrieval, Harbin Institute of Technology, Harbin, China.
Pattern separation and pattern completion in the hippocampus play a critical role in episodic learning and memory. However, there is limited empirical evidence supporting the role of the hippocampal circuit in these processes during complex continuous experiences. In this study, we analyzed high-resolution fMRI data from the "Forrest Gump" open-access dataset (16 participants) using a sliding-window temporal autocorrelation approach to investigate whether the canonical hippocampal circuit (DG-CA3-CA1-SUB) shows evidence consistent with the occurrence of pattern separation or pattern completion during a naturalistic audio movie task.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!